Conclusions Neoadjuvant chemotherapy is a feasible treatment option to allow for interval cytoreductive surgery in patients with advanced endometrial cancer not amenable to primary debulking. Patients who undergo surgery after chemotherapy have significantly improved progression free and overall survival.

IGCS20_1477

PRIMARY SYMPTOMS IN WOMEN WITH DIFFERENT HISTOPATHOLOGICAL SUBTYPES OF GYNAECOLOGICAL SARCOMA – RESULTS OF A PROSPECTIVE INTERGROUP REGISTRY FOR GYNAECOLOGICAL SARCOMA (REGSA – NOGGO RU1)

1E Roser*, 1K Pietzner, 1S Brucker, 1P Harter, 1D Zocholl, 1A Gimpel, 1M Kaldor, 1M Bossart, 1H Strauß, 1P Wimberger, 1R Armbrust, 1C Marth, 1T Felmi, 1P Jurikova, 1A Mustea, 1S Selhofer. 1Charité Universitätsmedizin Berlin, Department of Gynecology with Center for Oncological Surgery, Campus Virchow Clinic, Germany; 1University of Tübingen, Department of Gynecology and Obstetrics, Germany; 1Europäische Kliniken Essen-Mitte, Department of Gynecology and Gynecological Oncology, Germany; 1Charité Universitätsmedizin Berlin, Institute of Biometry and Clinical Epidemiology, Germany; 1North-Eastern German Society of Gynaecological Oncology, NOGGO e. V., Germany; 1University Clinic Giessen and Marburg, Department of Gynecology and Obstetrics, Germany; 1University Medical Center Freiburg, Department of Gynecology and Obstetrics, Germany; 1University of Halle, Department of Gynecology, Germany; 1Carl-Gustav-Carus University Dresden, Department of Gynecology and Obstetrics, Germany; 1Medical University of Innsbruck, Department of Obstetrics and Gynecology, Austria; 1Charité – Universitätsmedizin Berlin, Department of Gynecology and Gynecological Oncology, Germany; 1Heinrich-Heine University of Düsseldorf, Department of Gynecology and Obstetrics, Germany; 1Klinikum Passau, Department of Gynecology and Obstetrics, Germany; 1University of Bonn, Department of Gynaecology and Gynecological Oncology, Germany

10.1136/ijgc-2020-IGCS.380

Introduction Gynaecological sarcomas are rare and there is very limited evidence about symptoms at primary diagnosis. Most knowledge is based on retrospective analysis. Methods We present data of 410 patients (pts) in the primary situation. Overall, 87.91% of pts had documented symptom data, which were analysed descriptively. A distinction was made between pre- (prem., ≤52 yrs) and postmenopausal (postm., >52 yrs). Results The average age of pts was 56 yrs (range 15–88 yrs). Leiomyosarcoma (LMS) was diagnosed in 44.7%, endometrial stromal sarcoma (ESS) in 26.6% (62.6% low grade (LG-ESS) and 37.4% high grade (HG-ESS)). Undifferentiated sarcoma (US) and adenosarcoma (AS) were observed in 5.7% and 8.7% respectively. In prem. and postm. pts with LMS, the leading symptom (LS) was abdominal pain (ap) in 34.4%, and 39.5% respectively. In prem. HG-ESS the LS were ap and bleeding disorders (bd) in both 33.3%. In postm. HG-ESS and prem. LG-ESS the LS was vaginal bleeding (vb) in 29% and 33.3% respectively. In prem. AS the LS was ap in 27.3%, whereas in postm. AS it was postmenopausal bleeding (pb) in 29.2%. In prem. US the LS were bd and vb both at 66.7%. In postm. US the LS was ap in 47.4%. Conclusions We analyzed the LS of different histopathological subtypes in primary gynaecological sarcoma for the first time. Bleeding disorders and abdominal pain are the main symptoms in all subtypes. Symptoms are heterogeneous and about every 5th woman reported unspecific symptoms. This underlines the importance of awareness for gynaecological sarcoma.